DAFTAR PUSTAKA

1. Monica, P. Sindrom Stevens-Johnson. Available from:

http://elib.fk.uwks.ac.id/. 2013.

2. Adithan, C. Stevens-Johnson Syndrome In Drug Alert. Departement of

Pharmacology. JIPMER.2(1). Avaliable from: http//www.jipmer.edu.
2006.

3. Fernando, S.L., Broadfoot, A.J. Prevention Of Severe Cutaneous Adverse

Drug Reactions: The Emerging Value Of Pharmacogenetic Screening.
CMAJ. 2010; 182(5): hal. 476-80.

4. Foster, C.S. Stevens-Johnson Syndrome. Medscape. Available from:

http://emedicine.medscape.com/.2013.

5. Djuanda A. Sindrom Stevens-Johnson. Ilmu Penyakit Kulit dan Kelamin.

Bagian Ilmu Penyakit Kulit dan Kelamin Fakultas Kedokteran Universitas
Indonesia. Balai Penerbit Fakultas Kedokteran Universitas Indonesia.
Edisi 6. Jakarta. 2013: hal.163-5.

6. Williams, M. Stevens-Johnson Syndrome. Availabl from:

http://www.patient.co.uk.2013.

7. Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J.,
Wolff K. Epiermal Necrolysis (Stevens-Johnson Syndrome and Toxic
Epidermal Necrolysis). Fitzpatrick’s Dermatology in General Medicine.
New York: Mc Graw Hill Medical; 2012. Hal 439.48.

8. Mockenhaupt, M. The Current Understanding Of Stevens-Johnson

Syndrome And Toxic Epidermal Necrolysis. Expert Review Clinical
Immunology. 2011;7(6): hal. 803-15.

9. Harr, T., French, L.E. Toxic Epidermal Necrolysis And Stevens-Johnson

Syndrome. Orphanet Journal of Rare Disease. 2010;5: hal.39.

27